Alvotech sa
ALVO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
ALVO 近期報酬表現
1.04%
Alvotech sa
0.98%
同產業平均
0.02%
S&P500
與 ALVO 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PHVS | Pharvaris nv | 2 分 | 1 分 | 4 分 | 3 分 | 1 分 | |
TNXP | Tonix pharmaceuticals holding corp | 1 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
SMMT | Summit therapeutics inc | 2 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
MDGL | Madrigal pharmaceuticals inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
LQDA | Liquidia corp | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 |
- PHVS Pharvaris nv價值 2 分趨勢 1 分波段 4 分籌碼 3 分股利 1 分查看更多
ALVO 公司資訊
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company's pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.